These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 18639973)

  • 21. Editorial comment on: Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts.
    Moul JW; Tang P; Sun L
    Eur Urol; 2010 Mar; 57(3):452. PubMed ID: 19303696
    [No Abstract]   [Full Text] [Related]  

  • 22. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.
    D'Amico AV; Chen MH
    J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151
    [No Abstract]   [Full Text] [Related]  

  • 23. Editorial comment on: Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us?
    Stanislaus P; Seitz M
    Eur Urol; 2009 Apr; 55(4):909-10. PubMed ID: 18485577
    [No Abstract]   [Full Text] [Related]  

  • 24. Editorial comment on: Is prostate-specific antigen velocity selective for clinically significant prostate cancer in screening? European Randomized Study of Screening for Prostate Cancer (Rotterdam).
    Terris MK
    Eur Urol; 2009 Feb; 55(2):392; discussion 393. PubMed ID: 18353530
    [No Abstract]   [Full Text] [Related]  

  • 25. Radial distance of extraprostatic extension measured by an ocular micrometer is an independent predictor of prostate-specific antigen recurrence: a new proposal for the substaging of pT3a prostate cancer.
    Epstein JI
    Am J Surg Pathol; 2008 Feb; 32(2):337-8; author reply 338-40. PubMed ID: 18223339
    [No Abstract]   [Full Text] [Related]  

  • 26. In reply to Dr. Lee: are prostate cancers created equal?
    Lawrence G
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1276; author reply 1276-7. PubMed ID: 19857792
    [No Abstract]   [Full Text] [Related]  

  • 27. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.
    Thompson IM; Ankerst DP; Etzioni R; Wang T
    J Urol; 2008 Oct; 180(4):1219-22. PubMed ID: 18707707
    [No Abstract]   [Full Text] [Related]  

  • 28. Editorial comment.
    Makarov DV
    J Urol; 2009 Nov; 182(5):2255-6. PubMed ID: 19758643
    [No Abstract]   [Full Text] [Related]  

  • 29. Editorial comment.
    Naselli A
    J Urol; 2009 Nov; 182(5):2256. PubMed ID: 19758664
    [No Abstract]   [Full Text] [Related]  

  • 30. Editorial comment.
    Mann MJ
    J Urol; 2010 Mar; 183(3):1009. PubMed ID: 20092841
    [No Abstract]   [Full Text] [Related]  

  • 31. Editorial comment. The prognosis of the individual patient with prostate has made no quantum leaps during the past 10 years.
    Miller K
    Urology; 2009 Jun; 73(6):1334; author reply 1334-5. PubMed ID: 19482153
    [No Abstract]   [Full Text] [Related]  

  • 32. Editorial comment. Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening.
    Bañez LL
    Urology; 2010 Nov; 76(5):e4. PubMed ID: 21056250
    [No Abstract]   [Full Text] [Related]  

  • 33. Editorial comment.
    Donnelly B
    J Urol; 2009 Sep; 182(3):937; discussion 937. PubMed ID: 19616222
    [No Abstract]   [Full Text] [Related]  

  • 34. Editorial comment.
    Chin JL
    J Urol; 2009 Sep; 182(3):937; discussion 937. PubMed ID: 19616240
    [No Abstract]   [Full Text] [Related]  

  • 35. When watchful waiting is right choice for prostate cancer.
    Johns Hopkins Med Lett Health After 50; 2006 Oct; 18(8):1-2. PubMed ID: 17146873
    [No Abstract]   [Full Text] [Related]  

  • 36. Editorial comment.
    Carter HB
    Urology; 2009 Jul; 74(1):183; aurhor reply 183-4. PubMed ID: 19567300
    [No Abstract]   [Full Text] [Related]  

  • 37. Defining and treating high-risk prostate cancer: can we do better?
    Gerber L; Bañez LL; Freedland SJ
    Eur Urol; 2010 Jul; 58(1):8-9. PubMed ID: 20363552
    [No Abstract]   [Full Text] [Related]  

  • 38. Sweet's syndrome in prostate cancer.
    Glendenning J; Khoo V
    Prostate Cancer Prostatic Dis; 2008; 11(4):397-8. PubMed ID: 18227857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Baseline staging of newly diagnosed prostate cancer: a summary of the literature.
    Prando A
    Int Braz J Urol; 2004; 30(4):341-2. PubMed ID: 15679977
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.